TROP-2 ADCs in NSCLC
Expert Perspectives on TROP-2–Targeting ADCs for Advanced NSCLC

Released: July 15, 2024

Expiration: July 14, 2025

Narjust Florez
Narjust Florez, MD

Activity

Progress
1
Course Completed

In this commentary, Narjust Florez, MD, FASCO, engages learners on Twitter/X and provides real-word perspectives on novel and emerging TROP-2–targeting antibody–drug conjugates (ADCs) for the treatment of advanced NSCLC.

 

Image 1:

Image 2:

Image 3:

Image 4:

Image 5:

Image 6:

Image 7:

Image 8:

Image 9:

Image 10:

Image 11:

Poll

1.

If TROP-2–targeting ADCs are approved in the second-line setting for advanced NSCLC, how likely are you to incorporate this therapy into your clinical practice?

Submit